389 related articles for article (PubMed ID: 30650187)
21. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.
Jiang Z; Chu PG; Woda BA; Rock KL; Liu Q; Hsieh CC; Li C; Chen W; Duan HO; McDougal S; Wu CL
Lancet Oncol; 2006 Jul; 7(7):556-64. PubMed ID: 16814207
[TBL] [Abstract][Full Text] [Related]
22. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
24. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
Douglas ML; Richardson MM; Nicol DL
Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
[TBL] [Abstract][Full Text] [Related]
25. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
27. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
28. Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma.
Papworth K; Bergh A; Grankvist K; Ljungberg B; Sandlund J; Rasmuson T
Acta Oncol; 2013 Jan; 52(1):159-65. PubMed ID: 22731830
[TBL] [Abstract][Full Text] [Related]
29. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas.
Jiang Z; Lohse CM; Chu PG; Wu CL; Woda BA; Rock KL; Kwon ED
Cancer; 2008 Jun; 112(12):2676-82. PubMed ID: 18412154
[TBL] [Abstract][Full Text] [Related]
30. Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.
Müller T; Tolkach Y; Stahl D; Steiner S; Hauser S; Ellinger J; Rabien A; Ralla B; Jung K; Stephan C; Kristiansen G
Clin Genitourin Cancer; 2019 Feb; 17(1):e167-e175. PubMed ID: 30448104
[TBL] [Abstract][Full Text] [Related]
31. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
32. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
34. Implications of MTHFD2 expression in renal cell carcinoma aggressiveness.
Silva RVN; Berzotti LA; Laia MG; Araújo LS; Silva CA; Ribeiro KB; Brandão M; Michelleti AMR; Machado JR; Lira RCP
PLoS One; 2024; 19(2):e0299353. PubMed ID: 38422037
[TBL] [Abstract][Full Text] [Related]
35. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
[TBL] [Abstract][Full Text] [Related]
36. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
38. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract][Full Text] [Related]
39. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
[TBL] [Abstract][Full Text] [Related]
40. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
